These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 34093744)

  • 1. Novel therapeutics for patients with well-differentiated gastroenteropancreatic neuroendocrine tumors.
    Das S; Dasari A
    Ther Adv Med Oncol; 2021; 13():17588359211018047. PubMed ID: 34093744
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The evolution of PRRT for the treatment of neuroendocrine tumors; What comes next?
    Harris PE; Zhernosekov K
    Front Endocrinol (Lausanne); 2022; 13():941832. PubMed ID: 36387893
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-world comparison of healthcare resource utilization and costs of [
    Cox T; O'Connell M; Leeuwenkamp O; Palimaka S; Reed N
    Curr Med Res Opin; 2022 Aug; 38(8):1305-1317. PubMed ID: 35418254
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined use of 177Lu-DOTATATE and metronomic capecitabine (Lu-X) in FDG-positive gastro-entero-pancreatic neuroendocrine tumors.
    Nicolini S; Bodei L; Bongiovanni A; Sansovini M; Grassi I; Ibrahim T; Monti M; Caroli P; Sarnelli A; Diano D; Di Iorio V; Grana CM; Cittanti C; Pieri F; Severi S; Paganelli G
    Eur J Nucl Med Mol Imaging; 2021 Sep; 48(10):3260-3267. PubMed ID: 33604690
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The predictive impact of dual somatostatin receptor/fluorodeoxyglucose (FDG) positron emission tomography (PET) in metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs): review of literature and a single institution experience.
    Mohamed A; Asa SL; Lee Z; Tirumani SH; Li Q; Avril N; Bajor D; Mahipal A; Chakrabarti S; Selfridge JE; Kardan A
    J Gastrointest Oncol; 2023 Apr; 14(2):1087-1094. PubMed ID: 37201086
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Survival predictors of
    Swiha MM; Sutherland DEK; Sistani G; Khatami A; Abazid RM; Mujoomdar A; Wiseman DP; Romsa JG; Reid RH; Laidley DT
    J Cancer Res Clin Oncol; 2022 Jan; 148(1):225-236. PubMed ID: 34110489
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peptide Receptor Radionuclide Therapy and the Treatment of Gastroentero-pancreatic Neuroendocrine Tumors: Current Findings and Future Perspectives.
    Hirmas N; Jadaan R; Al-Ibraheem A
    Nucl Med Mol Imaging; 2018 Jun; 52(3):190-199. PubMed ID: 29942397
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lutetium oxodotreotide (
    Smith-Palmer J; Leeuwenkamp OR; Virk J; Reed N
    BMC Cancer; 2021 Jan; 21(1):10. PubMed ID: 33402120
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcome analysis in patients with metastatic gastroenteropancreatic neuroendocrine tumors receiving peptide receptor radionuclide therapy with Lu-177-DOTATATE.
    Prétot D; Engel-Bicik I; Kenkel D; Kaufmann PA; Treyer V; Siebenhüner AR
    J Gastrointest Oncol; 2023 Jun; 14(3):1204-1217. PubMed ID: 37435198
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Clinical Guide to Peptide Receptor Radionuclide Therapy with
    Becx MN; Minczeles NS; Brabander T; de Herder WW; Nonnekens J; Hofland J
    Cancers (Basel); 2022 Nov; 14(23):. PubMed ID: 36497273
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peptide Receptor Radionuclide Therapy for Advanced Gastroenteropancreatic Neuroendocrine Tumors - from oncology perspective.
    Kolasińska-Ćwikła A; Łowczak A; Maciejkiewicz KM; Ćwikła JB
    Nucl Med Rev Cent East Eur; 2018; 21(2):. PubMed ID: 29741203
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neuroendocrine Tumor Therapy with Lutetium-177: A Literature Review.
    Maqsood MH; Tameez Ud Din A; Khan AH
    Cureus; 2019 Jan; 11(1):e3986. PubMed ID: 30972265
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Persistent Hematologic Dysfunction after Peptide Receptor Radionuclide Therapy with
    Bergsma H; van Lom K; Raaijmakers MHGP; Konijnenberg M; Kam BLBLR; Teunissen JJM; de Herder WW; Krenning EP; Kwekkeboom DJ
    J Nucl Med; 2018 Mar; 59(3):452-458. PubMed ID: 28775205
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Practical Considerations for Implementation of
    Soulek DK; Mastascusa NJ; Martin ME; Graves SA
    J Nucl Med Technol; 2022 Jun; ():. PubMed ID: 35701215
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Performance of 177Lu-DOTATATE-based peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumor: a multiparametric response evaluation correlating with primary tumor site, tumor proliferation index, and dual tracer imaging characteristics.
    Thapa P; Ranade R; Ostwal V; Shrikhande SV; Goel M; Basu S
    Nucl Med Commun; 2016 Oct; 37(10):1030-7. PubMed ID: 27243215
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Care Process Model to Deliver
    Kasi PM; Maige CL; Shahjehan F; Rodgers JM; Aloszka DL; Ritter A; Andrus ML; Mcmillan JM; Mody K; Sharma A; Jain MK
    Front Oncol; 2018; 8():663. PubMed ID: 30687638
    [No Abstract]   [Full Text] [Related]  

  • 17. Emerging Treatment Options for Gastroenteropancreatic Neuroendocrine Tumors.
    Cives M; Pelle' E; Strosberg J
    J Clin Med; 2020 Nov; 9(11):. PubMed ID: 33202931
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metastatic Grade 3 Neuroendocrine Tumor in Multiple Endocrine Neoplasia Type 1 Expressing Somatostatin Receptors.
    Graf A; Welch J; Bansal R; Mandl A; Parekh VI; Cochran C; Levy E; Nilubol N; Patel D; Sadowski S; Jha S; Agarwal SK; Millo C; Blau JE; Simonds WF; Weinstein LS; Del Rivero J
    J Endocr Soc; 2022 Oct; 6(10):bvac122. PubMed ID: 36111275
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of lutetium (
    Palmer J; Leeuwenkamp OR
    World J Clin Cases; 2020 Oct; 8(20):4793-4806. PubMed ID: 33195647
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.